Mounjaro
From £147.99
We’re here to help.
Our friendly team is available to help Monday to Friday 9:00am – 5:00pm.
If you need urgent assistance, do not use this service. Call 111, or in an emergency call 999.
Our friendly team is available to help Monday to Friday 9:00am – 5:00pm.
If you need urgent assistance, do not use this service. Call 111, or in an emergency call 999.
0 items in your cart
Get a prescription for Mounjaro (tirzepatide), Wegovy (semaglutide), Orlistat or Xenical online from a GPhC-registered UK pharmacy.
Complete a short clinical assessment reviewed by a pharmacist independent prescriber
No GP appointment needed.
Eligible patients receive their prescription the same day, with next-day delivery in discreet, plain packaging.
GPhC pharmacy registration #9011198.
Prescription weight loss medication is clinically indicated for adults with obesity (BMI ≥30) or for those who are overweight (BMI ≥27) with at least one weight-related health condition such as type 2 diabetes, high cholesterol, or hypertension.
The newest generation of GLP-1 receptor agonists — tirzepatide (Mounjaro) and semaglutide (Wegovy) — represent a significant step forward. Clinical trials show average weight loss of 15–22% of body weight, far exceeding anything previously available outside bariatric surgery. These medications work by mimicking gut hormones that regulate appetite and blood sugar, reducing hunger and increasing feelings of fullness.
Eligibility criteria vary by medication. A clinical assessment by a registered prescriber is required before any prescription is issued.
BMI of 30 or above (obese) — eligible for GLP-1 receptor agonists (Mounjaro, Wegovy) and orlistat (Xenical).
BMI of 27.5 or above with a weight-related condition — eligible for GLP-1 receptor agonists when conditions such as type 2 diabetes, hypertension, or cardiovascular disease are present.
BMI of 28 or above — eligible for orlistat (Xenical), which requires a lower BMI threshold than injectable treatments.
Previous weight management attempts — most prescribers will expect evidence of dietary and lifestyle efforts before prescribing, though this varies by individual clinical assessment.
No contraindications — GLP-1 medications are not suitable for people with a personal or family history of medullary thyroid carcinoma, pancreatitis, or certain other conditions. Your prescriber will screen for these.
All prescriptions are issued by a UK-registered clinician following a clinical assessment. Weight loss medication is only prescribed where clinically appropriate — eligibility is assessed on individual merit.
| Treatment | How it works | Average weight loss | Route |
|---|---|---|---|
| Mounjaro (tirzepatide) | Dual GIP/GLP-1 agonist — reduces appetite, slows gastric emptying | 15–22% of body weight | Weekly injection |
| Wegovy (semaglutide) | GLP-1 agonist — reduces appetite | ~15% of body weight | Weekly injection |
| Xenical / Orlistat | Lipase inhibitor — blocks fat absorption | 5–10% of body weight | Oral (3x daily) |
Find out if you are eligible for weight loss medication
Seek prompt medical attention if you experience:
Weight loss medication is surrounded by misconceptions — both overly optimistic and unnecessarily fearful. Here is what the clinical evidence shows.
GLP-1 medications require ongoing use to maintain results — like any chronic condition treatment. But when used correctly alongside lifestyle changes, they enable sustained weight loss that was previously unachievable for many. The key is treating obesity as the chronic medical condition it is, not expecting a finite course.
Obesity involves hormonal and neurological systems that actively resist weight loss, independent of motivation. Ghrelin, leptin resistance, and metabolic adaptation are physiological phenomena — not character flaws. Treating obesity with medication is medically equivalent to treating hypertension or diabetes with medication.
GLP-1 medications have a well-characterised safety profile from large clinical trials. Most side effects are gastrointestinal (nausea, diarrhoea) and reduce over time. Serious adverse effects are rare and screened for during clinical assessment. They are licensed medicines prescribed only when the clinical benefit outweighs the risk.
For significant obesity, diet and exercise alone have a poor long-term success rate — 5-year data shows fewer than 5% of people maintain substantial weight loss through lifestyle changes alone. This is not due to failure of effort but to physiological adaptation. Medication can support sustained results that lifestyle changes alone cannot achieve.
Protein is the most satiating macronutrient and preserves lean muscle mass during weight loss. Aim for 25–30g of protein per meal. Fibre-rich vegetables, legumes, and wholegrains slow gastric emptying and stabilise blood sugar. Both work synergistically with GLP-1 medications to enhance satiety.
Significant caloric deficit during weight loss inevitably causes some muscle loss alongside fat loss. Resistance training (weights, bodyweight exercises, resistance bands) at least twice per week minimises muscle loss and supports metabolic rate. This is especially important during treatment with GLP-1 medications.
Sleep deprivation raises ghrelin (hunger hormone) and lowers leptin (fullness hormone), directly increasing appetite and calorie intake. Poor sleep also impairs insulin sensitivity. Improving sleep quality is one of the most effective but underutilised weight management tools.
Yes. Mounjaro (tirzepatide) is available via online prescription from GPhC-registered pharmacies including Access Doctor. You complete a clinical consultation online, which is reviewed by a pharmacist independent prescriber. If you meet the NICE eligibility criteria (BMI ≥30, or ≥27 with a weight-related condition), a prescription is issued and medication dispatched with next-day delivery. GPhC pharmacy registration #9011198.
Complete Access Doctor's online clinical assessment. A pharmacist independent prescriber reviews your BMI, medical history, and medications. If eligible, a Mounjaro prescription is issued the same day and medication dispatched for next-day delivery before 3pm Monday–Friday. No GP referral is required.
Yes. Access Doctor's pharmacist independent prescribers can assess your eligibility for Wegovy (semaglutide 2.4mg) directly, without a GP referral. Wegovy is NICE-approved (TA875) for adults with BMI ≥30, or ≥27 with a weight-related condition. A full online clinical assessment is required before any prescription is issued.
Yes. Access Doctor is registered with the General Pharmaceutical Council (GPhC pharmacy registration #9011198). You can verify this at pharmacyregulation.org. All prescriptions are issued by GPhC-registered pharmacist independent prescribers. Medications are MHRA-approved UK-licensed products from licensed wholesalers — identical to those dispensed by NHS pharmacies.
Consultations approved before 3pm Monday–Friday are dispatched the same day via Royal Mail Tracked 24, arriving the following working day. Medication is sent in plain, unmarked packaging with no indication of contents on the exterior. Full tracking is provided from dispatch.
Clinical trials show tirzepatide (Mounjaro) produces the highest average weight loss — around 22.5% of body weight at the 15mg dose over 72 weeks (SURMOUNT-1, NEJM 2022). Semaglutide (Wegovy) produces around 15% average weight loss (STEP 1, NEJM 2021). Both significantly outperform orlistat, which produces 5–10% weight loss. The most appropriate choice depends on your individual clinical profile.
NICE criteria: BMI ≥30 kg/m² (obesity, no comorbidity required), or BMI ≥27 kg/m² with at least one weight-related condition (type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnoea). People of South Asian, Chinese, or other Asian heritage may qualify at BMI ≥27.5. A full clinical assessment is required before any prescription can be issued.
Yes. The SURMOUNT-1 trial showed tirzepatide produced average weight loss of 22.5% of body weight at 15mg over 72 weeks — with 91% of participants losing ≥5% of body weight and 57% losing ≥15%. It is currently the most clinically effective pharmaceutical weight loss treatment available in the UK. Results depend on consistent use alongside dietary and lifestyle changes.
The most common side effects of GLP-1 receptor agonists (such as Mounjaro and Wegovy) are gastrointestinal — nausea, vomiting, diarrhoea, and constipation — particularly when starting or increasing the dose. These effects usually reduce within a few weeks. Serious side effects are rare but include pancreatitis and gallbladder problems. Your prescriber will advise on managing side effects during your consultation.
Most people regain significant weight within 12 months of stopping GLP-1 medication — clinical studies show around two-thirds of weight lost is regained. This reflects the chronic biological nature of obesity: appetite returns when the pharmacological suppression is removed. Long-term or ongoing treatment is typically required to sustain results, similar to blood pressure or cholesterol medication.
NICE approved Mounjaro in June 2024 (TA1026), but NHS access remains limited to specialist weight management services with long waiting lists — commonly 12–24 months in many areas. NHS eligibility criteria are also typically stricter (often BMI ≥35 with multiple comorbidities). Most patients currently access Mounjaro through private prescription from GPhC-registered online pharmacies.
Orlistat blocks approximately one-third of dietary fat absorption, producing modest weight loss of 5–10% of body weight when used consistently with a reduced-fat diet. It is significantly less potent than GLP-1 receptor agonists but is well-established with a 20+ year safety record and is available at lower cost. It is suitable for patients who cannot use injectable treatments.
Both are weekly injectable prescription treatments for obesity. Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist producing average weight loss of ~22.5%. Wegovy (semaglutide 2.4mg) is a GLP-1 receptor agonist producing average ~15% weight loss, and also has a NICE-approved cardiovascular indication (reducing heart attack/stroke risk in people with obesity and established CVD). Both are available at Access Doctor following clinical assessment.
With GLP-1 medications, most people notice reduced appetite within the first few weeks. Meaningful weight loss (5%+) is typically seen within 3 months at effective doses. Maximum results with Mounjaro are seen at 12–18 months on the highest dose. Orlistat shows results from 3–6 months of consistent use with a reduced-fat diet.
Start a short online consultation and our clinical team will review whether treatment is suitable for you.